David H. Quach

428 total citations
14 papers, 329 citations indexed

About

David H. Quach is a scholar working on Oncology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, David H. Quach has authored 14 papers receiving a total of 329 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Immunology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in David H. Quach's work include CAR-T cell therapy research (9 papers), Immune Cell Function and Interaction (7 papers) and Nerve injury and regeneration (4 papers). David H. Quach is often cited by papers focused on CAR-T cell therapy research (9 papers), Immune Cell Function and Interaction (7 papers) and Nerve injury and regeneration (4 papers). David H. Quach collaborates with scholars based in United States and Philippines. David H. Quach's co-authors include Cliona M. Rooney, Warren G. Tourtellotte, Peter E. Campos, DeAnna L. Adkins, Mark D. Borromeo, Malcolm K. Brenner, Helen E. Heslop, Royce Ma, Mary K. McKenna and John Hicks and has published in prestigious journals such as Journal of Neuroscience, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

David H. Quach

13 papers receiving 325 citations

Peers

Countries citing papers authored by David H. Quach

Since Specialization

Citations

This map shows the geographic impact of David H. Quach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David H. Quach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David H. Quach more than expected).

Fields of papers citing papers by David H. Quach

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David H. Quach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David H. Quach. The network helps show where David H. Quach may publish in the future.

Co-authorship network of co-authors of David H. Quach

This figure shows the co-authorship network connecting the top 25 collaborators of David H. Quach. A scholar is included among the top collaborators of David H. Quach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David H. Quach. David H. Quach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy 2024 ·Cancer Immunology Research ·Pei Y. Teo, (unknown), David H. Quach, (unknown), Richard Ong, Anthony T.C. Goh, Alrina Tan, Chee H. Ng, Cheah C. Seh, Kar Wai Tan, Ivan D. Horak, Lionel Low	1
2	Rejection resistant CD30.CAR-modified Epstein-Barr virus-specific T cells as an off-the-shelf platform for CD30+ lymphoma 2024 ·SHILAP Revista de lepidopterología ·David H. Quach, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Cliona M. Rooney	5
3	OFF‐THE‐SHELF CD30.CAR‐MODIFIED EPSTEIN‐BARR VIRUS‐SPECIFIC T CELLS (CD30.CAR EBVSTS) PROVIDE A SAFE AND EFFECTIVE THERAPY FOR PATIENTS WITH HODGKIN LYMPHOMA (HL) 2023 ·Hematological Oncology ·Carlos A. Ramos, David H. Quach, Premal Lulla, Rayne H. Rouce, Sandhya Sharma, (unknown), Nazila Nouraee, (unknown), (unknown), Sachin G. Thakkar, Birju Mehta, (unknown), Emily M. Hsieh, Huimin Zhang, Bambi Grilley, Natalia Lapteva, Malcolm K. Brenner, Helen E. Heslop, Cliona M. Rooney	8
4	CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells (CD30.CAR EBVSTs) Provide a Safe and Effective Off-the-Shelf Therapy for Patients with CD30-Positive Lymphoma 2022 ·Blood ·David H. Quach, Carlos A. Ramos, Premal Lulla, Sandhya Sharma, (unknown), Nazila Nouraee, (unknown), (unknown), (unknown), Sachin G. Thakkar, Birju Mehta, (unknown), Emily M. Hsieh, Huimin Zhang, Bambi Grilley, Malcolm K. Brenner, Helen E. Heslop, Rayne H. Rouce, Natalia Lapteva, Cliona M. Rooney	17
5	Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies 2022 ·Blood ·David H. Quach, Premal Lulla, Cliona M. Rooney	16
6	Safety and Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma 2021 ·Blood ·David H. Quach, Carlos A. Ramos, Premal Lulla, Sandhya Sharma, (unknown), (unknown), Sachin G. Thakkar, (unknown), Birju Mehta, (unknown), Eric C. Anderson, Emily M. Hsieh, Olga Dakhova, Huimin Zhang, Bambi Grilley, Malcolm K. Brenner, Helen E. Heslop, Rayne H. Rouce, Natalia Lapteva, Cliona M. Rooney	6
7	Engineered off-the-shelf therapeutic T cells resist host immune rejection 2020 ·Nature Biotechnology ·Feiyan Mo, Norihiro Watanabe, Mary K. McKenna, John Hicks, Madhuwanti Srinivasan, Diogo Gomes‐Silva, Erden Atilla, Tyler S. Smith, Pınar Ataca Atilla, Royce Ma, David H. Quach, Helen E. Heslop, Malcolm K. Brenner, Maksim Mamonkin	111
8	A Bank of CD30.CAR-Modified, Epstein-Barr Virus-Specific T Cells That Lacks Host Reactivity and Resists Graft Rejection for Patients with CD30-Positive Lymphoma 2020 ·Blood ·David H. Quach, (unknown), Sachin G. Thakkar, (unknown), Birju Mehta, (unknown), Eric Anderson, Emily M. Hsieh, Olga Dakhova, Huimin Zhang, Bambi Grilley, Malcolm K. Brenner, Helen E. Heslop, Carlos A. Ramos, Rayne H. Rouce, Natalia Lapteva, Cliona M. Rooney	5
9	A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells 2019 ·Journal of Translational Medicine ·David H. Quach, (unknown), Rayne H. Rouce, Cliona M. Rooney	19
10	A Sympathetic Neuron Autonomous Role for Egr3-Mediated Gene Regulation in Dendrite Morphogenesis and Target Tissue Innervation 2013 ·Journal of Neuroscience ·David H. Quach, (unknown), Katherine Gruner, Warren G. Tourtellotte	27
11	Egr3 Dependent Sympathetic Target Tissue Innervation in the Absence of Neuron Death 2011 ·PLoS ONE ·Lin Li, Laurie C. Eldredge, David H. Quach, Avinash Honasoge, Katherine Gruner, Warren G. Tourtellotte	5
12	Egr3 is a transcriptional regulator required for normal target tissue innervation during sympathetic nervous system development 2010 ·The FASEB Journal ·David H. Quach, Lin Li, Laurie C. Eldredge, Avinash Honasoge, Katherine Gruner, Warren G. Tourtellotte	0
13	Abnormal sympathetic nervous system development and physiological dysautonomia in Egr3-deficient mice 2008 ·Development ·Laurie C. Eldredge, Xiaoguang Gao, David H. Quach, Lin Li, Xiaoqiang Han, Jon W. Lomasney, Warren G. Tourtellotte	40
14	Epidural cortical stimulation enhances motor function after sensorimotor cortical infarcts in rats 2006 ·Experimental Neurology ·DeAnna L. Adkins, Peter E. Campos, David H. Quach, Mark D. Borromeo, (unknown), (unknown)	69

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact